Takeda Pharmaceutical Company Limited Peer Comparison

Metric Value Ranking
Market Cap $47.1 Billion 2/18 ZTS
$84.5B		 TAK
$47.1B		 TEVA
$20.9B		 VTRS
$13.9B		 NBIX
$12.2B		 CTLT
$10.9B		 ELAN
$7.6B		 PBH
$3.7B		 BHC
$2.3B		 DCPH
$2.2B		 AMPH
$2.2B		 COLL
$1.2B		 PAHC
$786.6M		 PCRX
$677.1M		 SIGA
$568.8M		 EBS
$403.7M		 ESPR
$337.5M		 EGRX
$57.0M
Gross Margin 54% 10/18 EBS
100%		 NBIX
97%		 DCPH
92%		 ESPR
79%		 EGRX
74%		 ZTS
72%		 PCRX
67%		 COLL
63%		 BHC
59%		 TAK
54%		 PBH
53%		 AMPH
50%		 TEVA
49%		 ELAN
47%		 SIGA
44%		 VTRS
38%		 PAHC
32%		 CTLT
30%
Profit Margin 8% 7/18 ZTS
26%		 AMPH
21%		 PBH
18%		 COLL
13%		 PCRX
11%		 NBIX
11%		 TAK
8%		 EGRX
8%		 SIGA
8%		 CTLT
2%		 PAHC
0%		 BHC
0%		 ELAN
-4%		 VTRS
-9%		 TEVA
-20%		 ESPR
-84%		 EBS
-100%		 DCPH
-100%
EBITDA margin 34% 4/18 COLL
57%		 ZTS
40%		 AMPH
38%		 TAK
34%		 BHC
31%		 PBH
30%		 PCRX
28%		 TEVA
26%		 NBIX
26%		 ELAN
23%		 VTRS
21%		 EGRX
17%		 CTLT
8%		 PAHC
8%		 SIGA
6%		 ESPR
3%		 EBS
-80%		 DCPH
-105%
Quarterly Revenue $8.5 Billion 1/18 TAK
$8.5B		 TEVA
$4.2B		 VTRS
$3.8B		 BHC
$2.4B		 ZTS
$2.4B		 CTLT
$1.3B		 ELAN
$1.2B		 NBIX
$590.2M		 PAHC
$273.2M		 PBH
$267.1M		 EBS
$254.7M		 AMPH
$182.4M		 PCRX
$178.0M		 COLL
$145.3M		 ESPR
$73.8M		 EGRX
$64.6M		 DCPH
$45.0M		 SIGA
$21.8M
Quarterly Earnings $666.5 Million 1/18 TAK
$666.5M 		ZTS
$624.0M 		NBIX
$65.0M 		PBH
$49.1M 		AMPH
$37.9M 		CTLT
$23.0M 		COLL
$19.6M 		PCRX
$18.9M 		BHC
$10.0M 		EGRX
$5.2M 		SIGA
$1.8M 		PAHC
$752,000 		DCPH
-$45.1M 		ELAN
-$50.0M 		ESPR
-$61.9M 		EBS
-$283.1M 		VTRS
-$326.4M 		TEVA
-$845.0M
Quarterly Free Cash Flow $151.0 Million 5/18 TEVA
$323.0M 		VTRS
$309.6M 		BHC
$299.7M 		ELAN
$166.0M 		TAK
$151.0M 		COLL
$67.1M 		AMPH
$63.1M 		PBH
$53.6M 		NBIX
$53.0M 		PCRX
$51.6M 		PAHC
$15.4M 		SIGA
$6.0M 		ZTS
-$0 		EGRX
-$132,000 		DCPH
-$54.7M 		ESPR
-$0 		CTLT
-$0 		EBS
-$0
Trailing 4 Quarters Revenue $30.9 Billion 1/18 TAK
$30.9B		 TEVA
$16.3B		 VTRS
$15.2B		 BHC
$9.2B		 ZTS
$8.9B		 ELAN
$4.5B		 CTLT
$4.4B		 NBIX
$2.1B		 PBH
$1.1B		 EBS
$1.1B		 PAHC
$1.0B		 AMPH
$690.4M		 PCRX
$690.3M		 COLL
$576.7M		 ESPR
$277.8M		 EGRX
$257.6M		 DCPH
$174.9M		 SIGA
$173.0M
Trailing 4 Quarters Earnings $1.0 Billion 2/18 TAK
$8.5B 		TEVA
$4.2B 		VTRS
$3.8B 		BHC
$2.4B 		ZTS
$2.4B 		CTLT
$1.3B 		ELAN
$1.2B 		NBIX
$590.2M 		PAHC
$273.2M 		PBH
$267.1M 		EBS
$254.7M 		AMPH
$182.4M 		PCRX
$178.0M 		COLL
$145.3M 		ESPR
$73.8M 		EGRX
$64.6M 		DCPH
$45.0M 		SIGA
$21.8M
Quarterly Earnings Growth 7% 7/18 SIGA
164% 		EGRX
155% 		CTLT
127% 		COLL
51% 		ELAN
48% 		AMPH
45% 		TAK
7% 		TEVA
2% 		DCPH
2% 		ZTS
-7% 		PBH
-8% 		EBS
-8% 		ESPR
-24% 		PCRX
-27% 		NBIX
-32% 		BHC
-62% 		PAHC
-93% 		VTRS
-224%
Annual Earnings Growth -18% 13/18 SIGA
1591% 		COLL
354% 		NBIX
353% 		PCRX
294% 		PBH
131% 		BHC
94% 		TEVA
72% 		ESPR
69% 		AMPH
60% 		EBS
27% 		ZTS
1% 		DCPH
-4% 		TAK
-18% 		CTLT
-30% 		EGRX
-87% 		PAHC
-94% 		VTRS
-169% 		ELAN
-692%
Quarterly Revenue Growth 14% 7/18 SIGA
271% 		ESPR
186% 		DCPH
35% 		NBIX
30% 		AMPH
25% 		CTLT
22% 		TAK
14% 		ELAN
12% 		BHC
11% 		ZTS
8% 		TEVA
7% 		COLL
7% 		PAHC
7% 		PCRX
5% 		VTRS
-3% 		PBH
-4% 		EGRX
-13% 		EBS
-25%
Annual Revenue Growth 12% 8/18 SIGA
461% 		ESPR
181% 		EBS
32% 		NBIX
24% 		DCPH
23% 		AMPH
22% 		BHC
15% 		TAK
12% 		TEVA
10% 		ZTS
9% 		PCRX
6% 		CTLT
5% 		PAHC
3% 		COLL
1% 		VTRS
1% 		PBH
-2% 		ELAN
-7% 		EGRX
-39%
Cash On Hand $5.6 Billion 1/18 TAK
$5.6B 		TEVA
$2.3B 		ZTS
$1.6B 		VTRS
$918.5M 		BHC
$622.9M 		ELAN
$416.0M 		CTLT
$289.0M 		PCRX
$247.1M 		AMPH
$189.9M 		ESPR
$189.3M 		COLL
$172.9M 		NBIX
$139.7M 		SIGA
$106.9M 		DCPH
$91.2M 		PAHC
$70.6M 		EBS
$69.7M 		PBH
$34.3M 		EGRX
$15.4M
Short Term Debt $3.1 Billion 1/18 TAK
$3.1B 		VTRS
$2.5B 		TEVA
$2.1B 		BHC
$451.9M 		EBS
$415.2M 		ELAN
$213.0M 		COLL
$184.4M 		CTLT
$48.0M 		NBIX
$35.4M 		PCRX
$9.1M 		EGRX
$8.3M 		PBH
$4.4M 		AMPH
$4.2M 		DCPH
$3.6M 		ESPR
$2.7M 		SIGA
$523,889 		ZTS
-$0 		PAHC
-$0
Long Term Debt $35.3 Billion 1/18 TAK
$35.3B		 BHC
$21.2B		 TEVA
$16.5B		 VTRS
$14.7B		 ZTS
$6.7B		 ELAN
$5.5B		 CTLT
$4.9B		 PBH
$1.1B		 PCRX
$589.3M		 AMPH
$586.9M		 COLL
$369.5M		 PAHC
$282.3M		 ESPR
$266.5M		 NBIX
$256.2M		 EGRX
$61.9M		 DCPH
$21.4M		 SIGA
$1.1M		 EBS
$0
PE 44.87 2/18 PAHC
323.56		 TAK
44.87		 NBIX
36.08		 ZTS
36.06		 PBH
18.14		 AMPH
13.28		 COLL
12.13		 PCRX
10.65		 SIGA
6.77		 EGRX
3.66		 TEVA
-1.00		 ESPR
-1.00		 CTLT
-1.00		 EBS
-1.00		 DCPH
-1.00		 BHC
-1.00		 ELAN
-1.00		 VTRS
-1.00
PS 217.83 1/18 TAK
217.83		 DCPH
12.65		 ZTS
9.48		 NBIX
5.77		 PBH
3.34		 SIGA
3.29		 AMPH
3.20		 CTLT
2.49		 COLL
2.10		 ELAN
1.69		 TEVA
1.28		 ESPR
1.21		 PCRX
0.98		 VTRS
0.91		 PAHC
0.77		 EBS
0.37		 BHC
0.25		 EGRX
0.22
PB 0.86 13/18 ZTS
17.04		 DCPH
7.00		 COLL
5.60		 NBIX
4.88		 SIGA
3.39		 TEVA
3.18		 AMPH
3.10		 PAHC
3.06		 CTLT
3.03		 PBH
2.21		 ELAN
1.28		 EBS
1.04		 TAK
0.86		 PCRX
0.77		 VTRS
0.71		 EGRX
0.23		 ESPR
0.00		 BHC
0.00
PC 8.36 11/18 PBH
108.62		 NBIX
87.61		 ZTS
53.71		 CTLT
37.82		 DCPH
24.26		 ELAN
18.24		 VTRS
15.16		 AMPH
11.65		 PAHC
11.14		 TEVA
9.25		 TAK
8.36		 COLL
7.01		 EBS
5.79		 SIGA
5.32		 EGRX
3.71		 BHC
3.65		 PCRX
2.74		 ESPR
1.78
Liabilities to Equity 1.08 10/18 TEVA
5.47		 COLL
3.86		 EBS
2.92		 PAHC
2.83		 ZTS
1.85		 CTLT
1.71		 ELAN
1.32		 VTRS
1.32		 AMPH
1.09		 TAK
1.08		 PBH
0.97		 PCRX
0.87		 EGRX
0.61		 DCPH
0.33		 NBIX
0.32		 SIGA
0.15		 ESPR
0.00		 BHC
0.00
ROA 0.00 9/18 SIGA
44% 		ZTS
17% 		AMPH
11% 		NBIX
10% 		COLL
9% 		PBH
6% 		PCRX
4% 		EGRX
4% 		TAK
0% 		PAHC
0% 		BHC
0% 		TEVA
-1% 		VTRS
-1% 		ELAN
-9% 		CTLT
-10% 		ESPR
-28% 		EBS
-39% 		DCPH
-45%
ROE 0.00 12/18 SIGA
50% 		ZTS
47% 		COLL
46% 		ESPR
29% 		AMPH
23% 		NBIX
14% 		PBH
12% 		PCRX
7% 		EGRX
6% 		BHC
3% 		PAHC
1% 		TAK
0% 		VTRS
-3% 		TEVA
-7% 		ELAN
-21% 		CTLT
-28% 		DCPH
-60% 		EBS
-153%
Current Ratio 1.93 7/18 SIGA
7.68		 NBIX
4.15		 DCPH
4.01		 EGRX
2.65		 PCRX
2.15		 PBH
2.03		 TAK
1.93		 AMPH
1.92		 ELAN
1.76		 VTRS
1.76		 CTLT
1.59		 ZTS
1.54		 PAHC
1.35		 EBS
1.34		 COLL
1.26		 TEVA
1.19		 BHC
0.99		 ESPR
0.51
Quick Ratio 0.10 10/18 PAHC
323.56		 TAK
44.87		 NBIX
36.08		 ZTS
36.06		 PBH
18.14		 AMPH
13.28		 COLL
12.13		 PCRX
10.65		 SIGA
6.77		 EGRX
3.66		 TEVA
-1.00		 ESPR
-1.00		 CTLT
-1.00		 EBS
-1.00		 DCPH
-1.00		 BHC
-1.00		 ELAN
-1.00		 VTRS
-1.00
Long Term Debt to Equity 0.65 10/18 TEVA}
2.60		 COLL}
1.71		 ZTS}
1.36		 CTLT}
1.35		 PAHC}
1.10		 ELAN}
0.92		 AMPH}
0.82		 VTRS}
0.75		 PCRX}
0.67		 TAK}
0.65		 PBH}
0.65		 EGRX}
0.25		 NBIX}
0.10		 DCPH}
0.07		 SIGA}
0.01		 EBS}
0.00		 ESPR}
-0.77		 BHC}
-18.05
Debt to Equity 0.70 11/18 TEVA
2.98		 COLL
2.58		 ZTS
1.36		 CTLT
1.36		 PAHC
1.10		 EBS
1.07		 ELAN
0.96		 VTRS
0.89		 AMPH
0.87		 PCRX
0.74		 TAK
0.70		 PBH
0.66		 EGRX
0.28		 NBIX
0.12		 DCPH
0.08		 SIGA
0.01		 ESPR
-0.78		 BHC
-18.43
Burn Rate 2.59 4/18 PCRX
35.43		 PAHC
6.70		 COLL
4.19		 TAK
2.59		 ESPR
2.58		 DCPH
1.95		 CTLT
1.58		 ELAN
1.29		 TEVA
1.11		 BHC
0.65		 VTRS
0.60		 EBS
0.18		 NBIX
-3.04		 ZTS
-4.44		 PBH
-7.95		 AMPH
-14.15		 EGRX
-25.01		 SIGA
-64.56
Cash to Cap 0.12 8/18 ESPR
0.56		 PCRX
0.36		 EGRX
0.27		 BHC
0.27		 SIGA
0.19		 EBS
0.17		 COLL
0.14		 TAK
0.12		 TEVA
0.11		 AMPH
0.09		 PAHC
0.09		 VTRS
0.07		 ELAN
0.05		 DCPH
0.04		 CTLT
0.03		 ZTS
0.02		 PBH
0.01		 NBIX
0.01
CCR 0.23 10/18 BHC
29.98		 PAHC
20.42		 COLL
3.42		 SIGA
3.25		 PCRX
2.73		 AMPH
1.66		 DCPH
1.21		 PBH
1.09		 NBIX
0.82		 TAK
0.23		 ZTS
0.00		 EGRX
-0.03		 TEVA
-0.38		 VTRS
-0.95		 ELAN
-3.32		 ESPR
 CTLT
 EBS
EV to EBITDA 11.35 15/18 SIGA}
379.70		 ESPR}
161.82		 CTLT}
146.67		 ZTS}
95.33		 NBIX}
79.84		 PBH}
59.74		 ELAN}
46.38		 PAHC}
45.71		 VTRS}
38.67		 AMPH}
38.08		 TEVA}
34.99		 BHC}
31.33		 PCRX}
21.64		 COLL}
19.27		 TAK}
11.35		 EGRX}
10.41		 EBS}
-3.68		 DCPH}
-45.43
EV to Revenue 151.45 1/18 TAK
151.45		 DCPH
12.27		 ZTS
10.06		 NBIX
5.85		 PBH
4.30		 AMPH
3.83		 CTLT
3.54		 ELAN
2.86		 COLL
2.77		 SIGA
2.68		 BHC
2.54		 TEVA
2.31		 VTRS
2.00		 PCRX
1.56		 ESPR
1.50		 PAHC
0.98		 EBS
0.68		 EGRX
0.43

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions